Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights gained from more than two decades of providing guidance to biopharmaceutical companies.
[slideshare id=226958353&doc=yalifriedman-pharmaresourceplanningportfoliomanagement-evaluatinginnovativeportfoliosandpreparingfor-200205031852]
